Is Designing Babies Unethical—or a Moral Imperative?

Key Takeaways

Biotech companies now offer embryo screening beyond disease risk, promising 'optimization' of traits like intelligence and longevity.
The episode features a debate on whether germline gene editing is a moral imperative to prevent severe diseases or an unethical 'designer baby' concept.
Proponents argue for regulated genetic interventions to prevent suffering from debilitating single-gene disorders, comparing it to other medical advancements.
Opponents raise concerns about eugenics, unknown multi-generational risks, and viewing children as projects rather than gifts deserving unconditional acceptance.
A key distinction is drawn between somatic editing (non-heritable) for existing diseases and germline editing (heritable), which poses significant ethical and safety questions.

Biotech companies, such as Nucleus Genomics, now offer embryo screening for IVF patients that goes beyond disease risk, promising 'optimization' of traits like intelligence, longevity, and physical characteristics.
The debate explores if enhancing health and intelligence at a molecular level before birth is an ethical choice and potential moral imperative, or if it crosses a line by 'playing God'.
Jamie Metzl, a technology futurist and WHO expert on genome editing, and Dr. Allyson Berent, an advocate for Angelman Syndrome therapeutics, argue for the ethical imperative.
O. Carter Snead, a bioethicist and law professor, and Dr. Lydia Dugdale, a physician and medical ethicist, argue against the ethics of designing babies.

Jamie Metzl advocates for differentiating irresponsible applications of heritable human genome editing from potentially life-saving ones, drawing parallels to agriculture and vaccines.
O. Carter Snead defines 'designing a baby' as engineering for elective traits, distinguishing it from embryo sorting.
Snead argues that babies are a gift, not property, and that parents owe them unconditional love and gratitude, opposing rational mastery over a child's genetic makeup.

Dr. Allyson Berent, with a career in veterinary medicine developing innovative treatments, became a force for genetic research after her daughter, Quincy, was diagnosed at five months with Angelman syndrome.
Angelman syndrome is a severe neurogenetic disorder caused by a single faulty gene, profoundly impacting Quincy's speech, independence, and physical abilities.
Berent's personal experience motivated her to oversee gene therapy development at the Foundation for Angelman Syndrome Therapeutics (FAST) and a biotechnology company.

Opponents argue that designing babies is an unethical eugenics project, drawing parallels to historical movements like 'fitter family contests' and the Nobel laureate sperm bank, which aimed to improve the human gene pool.
Historical attempts at 'optimal reproduction' led to the sterilization of individuals deemed 'unfit' in the U.S. and Germany, as well as atrocities committed by the Nazis.
The assertion that some lives are worth creating implies that other lives are not, potentially leading to the devaluation or destruction of human life, which is a reason for rejecting designer babies.

The concept of 'designer babies' is critiqued for emphasizing rational mastery and technical control, which could undermine the unconditional parental acceptance of a child, asserting that a child is an individual with inherent dignity, not a project.
Jamie Metzl clarifies that while current readiness for germline gene editing is lacking due to safety issues, the World Health Organization's recommendations do not equate to a permanent ban; he distinguishes therapeutic interventions from elective trait selection.
The discussion addresses eugenics in the context of embryo selection, with one speaker noting a personal sensitivity due to a Holocaust survivor parent, while acknowledging that optimizing for health, especially for hereditary fatal genetic disorders, is a valid consideration.

The conversation shifts to the possibility of a controlled regulatory framework for embryo editing, but a counterpoint highlights the current lack of regulation in the IVF context, citing examples like sex selection and trait selection already occurring.
A historical perspective on IVF notes the absence of regulation on sex and trait selection, questioning if a legal framework can adequately regulate embryo editing, particularly in light of past controversial figures associated with genetic selection.
The ethics of pre-implantation genetic diagnosis (PGD) for sex selection, which is common in the US, is debated, with one participant arguing it is unethical due to a lack of unconditional parental love, while also discussing germline editing for diseases like Huntington's.

A core ethical question is posed: Is the human germline sacred and unalterable, or is altering it, particularly for medical purposes, ethically permissible, especially considering the current unregulated landscape of IVF and potential future enhancements?
One speaker argues the debate is relevant now because heritable mitochondrial transfer treatments are already occurring in places like the UK, posing the question of whether parents should be denied the opportunity to remove deadly genetic mutations, framing it as a moral imperative.
Concerns are expressed that even carefully regulated genetic editing in one country could spread globally, exploited through financial or coercive means, driven by a 'technological imperative' and physician hubris, potentially leading to over-medicalization.

One participant argues that accepting a law to ban non-medical germline editing concedes the entire debate, as it implies a moral imperative to allow edits for specific medical conditions.
Postnatal and in utero gene therapy and editing are subject to significant FDA regulations focused on safety and efficacy, involving extensive testing, contrasting with the hypothetical germline editing.
The discussion highlights the distinction between treating debilitating diseases and selecting for elective traits, raising concerns about the potential for widespread, unforeseen consequences from extensive genetic modifications.

The history of IVF is revisited, noting initial controversies and subsequent widespread acceptance, along with industry lobbying efforts that prioritize reproductive autonomy, even for practices like sex selection.
Jamie Metzl argues that while human biology is complex, intervening in single-gene disorders represents a potential life-saving opportunity, advocating for a regulated framework for safe future applications rather than labeling the entire field unethical.
O. Carter Snead argues against 'designer babies,' emphasizing the distinction between enhancement and health, and urges a vote against germline gene therapy due to the current lack of safety, efficacy, and a robust regulatory framework.